Date published: 2026-5-15

1-800-457-3801

SCBT Portrait Logo
Seach Input

MAGE-C3 Inhibitors

Chemical inhibitors of MAGE-C3 can exert their influence by targeting critical components of signaling pathways that are essential for the protein's function. Dabrafenib, a BRAF inhibitor, can inhibit MAGE-C3 by interrupting the BRAF/MEK/ERK pathway, which is known to be essential for the post-translational modification or stabilization of various proteins, including the MAGE family. Similarly, Trametinib and Cobimetinib function as MEK inhibitors and can inhibit MAGE-C3 by disrupting downstream signaling of the RAS/RAF/MEK/ERK pathway, which is central to the regulation of protein activity within the cell. Vemurafenib, another BRAF inhibitor, can inhibit MAGE-C3 by obstructing the kinase activity necessary for its function or stability. LY3009120, targeting pan-RAF kinases, can inhibit MAGE-C3 by halting the RAF/MEK/ERK signaling cascade, thereby affecting proteins directly regulated by this pathway.

Encorafenib, as a BRAF inhibitor, can inhibit MAGE-C3 by interfering with MAPK pathway signaling mechanisms that MAGE-C3 may utilize. Binimetinib can inhibit MAGE-C3 by preventing MEK activation, thus impeding the signaling pathways that regulate MAGE-C3 activity. Sorafenib's multitargeted kinase inhibition can inhibit MAGE-C3 by disrupting various pathways, some of which may contribute to the post-translational modifications of MAGE-C3. Sunitinib, a receptor tyrosine kinase inhibitor, can inhibit MAGE-C3 by blocking critical signaling pathways that underpin the functional stability of proteins. Selumetinib, by specifically inhibiting MEK1/2, can inhibit MAGE-C3 by obstructing the MEK/ERK pathway, potentially a requirement for MAGE-C3's activity. Additionally, Pazopanib and Lenvatinib, as multikinase inhibitors, can inhibit MAGE-C3 by disrupting signal transduction through pathways involving receptor tyrosine kinases, which might be important for the regulation and function of MAGE-C3. These chemicals act on precise molecular targets within signaling cascades that are known to be important for the function of proteins such as MAGE-C3.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Dabrafenib

1195765-45-7sc-364477
sc-364477A
sc-364477B
sc-364477C
sc-364477D
5 mg
25 mg
50 mg
100 mg
10 g
$141.00
$260.00
$278.00
$411.00
$12485.00
6
(1)

Dabrafenib is a BRAF inhibitor that can inhibit MAGE-C3 by disrupting the BRAF/MEK/ERK pathway, which MAGE-C3 may utilize for post-translational modifications or stabilization.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$114.00
$166.00
$947.00
19
(1)

Trametinib is a MEK inhibitor that can inhibit MAGE-C3 by impeding the downstream signaling of the RAS/RAF/MEK/ERK pathway, which is involved in the regulation of numerous proteins including MAGE family proteins.

Cobimetinib

934660-93-2sc-507421
5 mg
$270.00
(0)

Cobimetinib selectively inhibits MEK1/2, potentially leading to decreased MAGE-C3 function by interfering with its associated signaling pathways that rely on MEK/ERK phosphorylation events.

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$117.00
$423.00
11
(1)

Vemurafenib targets BRAF V600E kinase, which can result in the inhibition of MAGE-C3 by blocking the pathway needed for its activity or expression stabilization.

LY3009120

1454682-72-4sc-507538
5 mg
$125.00
(0)

LY3009120 inhibits pan-RAF kinases and can inhibit MAGE-C3 function by halting the RAF/MEK/ERK signaling cascade, affecting proteins regulated by this pathway.

Encorafenib

1269440-17-6sc-507422
1 mg
$115.00
(0)

Encorafenib is a BRAF inhibitor which can inhibit MAGE-C3 by disrupting the normal signaling mechanisms in which MAGE-C3 might participate, particularly the MAPK pathway.

MEK 162

606143-89-9sc-488879
10 mg
$306.00
(0)

Binimetinib, a MEK inhibitor, can inhibit MAGE-C3 by preventing the activation of MEK proteins, thus impeding the signaling pathways that could regulate MAGE-C3 activities.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Sorafenib targets multiple kinases and can inhibit MAGE-C3 by disrupting various signaling pathways, including those that might contribute to MAGE-C3 post-translational modification.

Sunitinib Malate

341031-54-7sc-220177
sc-220177A
sc-220177B
10 mg
100 mg
3 g
$197.00
$520.00
$1093.00
4
(1)

Sunitinib is a receptor tyrosine kinase inhibitor that can inhibit MAGE-C3 by blocking signaling pathways that are critical for the function and stability of various proteins, possibly including MAGE-C3.

Selumetinib

606143-52-6sc-364613
sc-364613A
sc-364613B
sc-364613C
sc-364613D
5 mg
10 mg
100 mg
500 mg
1 g
$29.00
$82.00
$420.00
$1897.00
$3021.00
5
(1)

Selumetinib is a selective, non-ATP-competitive inhibitor of MEK1/2 that can inhibit MAGE-C3 by obstructing the MEK/ERK pathway, which may be necessary for MAGE-C3's functional role.